Index NDX, S&P 500
P/E -
EPS (ttm) -28.58
Insider Own 0.10%
Shs Outstand 158.00M
Perf Week 7.12%
Market Cap 31.48B
Forward P/E 65.21
EPS next Y 3.18
Insider Trans -7.15%
Shs Float 156.75M
Perf Month 5.48%
Income -4487.00M
PEG -
EPS next Q 0.02
Inst Own 91.10%
Short Float / Ratio 2.74% / 3.33
Perf Quarter -6.28%
Sales 4.45B
P/S 7.08
EPS this Y -655.90%
Inst Trans 2.86%
Short Interest 4.30M
Perf Half Y -4.94%
Book/sh 42.36
P/B 4.89
EPS next Y 134.61%
ROA -35.40%
Target Price 238.92
Perf Year -11.86%
Cash/sh 10.00
P/C 20.74
EPS next 5Y -
ROE -58.90%
52W Range 173.45 - 248.88
Perf YTD 2.53%
Dividend -
P/FCF -
EPS past 5Y -46.50%
ROI -45.50%
52W High -16.70%
Beta 1.17
Dividend % -
Quick Ratio 1.20
Sales past 5Y 10.70%
Gross Margin 63.20%
52W Low 19.52%
ATR 7.92
Employees 11500
Current Ratio 1.40
Sales Q/Q -11.10%
Oper. Margin -99.60%
RSI (14) 52.15
Volatility 3.20% 3.79%
Optionable Yes
Debt/Eq 0.33
EPS Q/Q -96.50%
Profit Margin -
Rel Volume 1.58
Prev Close 199.09
Shortable Yes
LT Debt/Eq 0.22
Earnings Apr 25 AMC
Payout -
Avg Volume 1.29M
Price 207.31
Recom 2.70
SMA20 2.93%
SMA50 -2.81%
SMA200 -1.32%
Volume 2,033,619
Change 4.13%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-25-23 Downgrade
Argus
Buy → Hold
Jan-05-23 Initiated
Scotiabank
Sector Perform
$216
Dec-12-22 Downgrade
Citigroup
Neutral → Sell
$200 → $180
Dec-07-22 Initiated
RBC Capital Mkts
Outperform
$282
Oct-04-22 Upgrade
SVB Leerink
Mkt Perform → Outperform
$220 → $270
Sep-28-22 Upgrade
Evercore ISI
In-line → Outperform
$170 → $250
Aug-25-22 Initiated
Credit Suisse
Neutral
$230
Jul-13-22 Downgrade
Barclays
Equal Weight → Underweight
$350 → $150
Jan-18-22 Upgrade
Stifel
Hold → Buy
$480
Jan-11-22 Upgrade
Barclays
Underweight → Equal Weight
Jan-07-22 Upgrade
BofA Securities
Underperform → Neutral
Jan-06-22 Resumed
Piper Sandler
Overweight
$450
Jan-06-22 Resumed
Morgan Stanley
Equal-Weight
$425
Oct-15-21 Resumed
Cowen
Outperform
$550
Aug-19-21 Downgrade
SVB Leerink
Outperform → Mkt Perform
$425
Jun-01-21 Upgrade
Evercore ISI
Underperform → In-line
$400
Mar-31-21 Upgrade
Canaccord Genuity
Hold → Buy
$445
Mar-31-21 Downgrade
Atlantic Equities
Overweight → Neutral
$390
Mar-03-21 Initiated
Barclays
Underweight
$325
Dec-22-20 Upgrade
Piper Sandler
Neutral → Overweight
$340 → $415
Show Previous Ratings
Jun-03-23 12:59PM (The Wall Street Journal)
Jun-02-23 04:28PM
03:49PM
01:42PM
12:44PM
11:31AM
Loading…
11:31AM
10:54AM
07:51AM
07:45AM
07:38AM
07:30AM
Jun-01-23 02:00PM
02:00PM
11:31AM
May-31-23 04:05PM
09:16AM
Loading…
09:16AM
May-30-23 06:40PM
06:35PM
09:15AM
May-29-23 11:42PM
May-27-23 07:00AM
May-26-23 08:00AM
06:48AM
12:00AM
May-25-23 05:47PM
05:00PM
03:16PM
02:59PM
02:47PM
02:45PM
02:16PM
Loading…
02:16PM
01:59PM
01:45PM (The Wall Street Journal)
01:25PM
10:19AM
10:03AM
May-24-23 08:58PM
02:00PM
10:15AM
12:00AM
May-23-23 07:57AM
May-22-23 08:24AM
May-20-23 10:00AM (The Wall Street Journal)
May-19-23 07:17PM
01:01PM
08:21AM
07:01AM
04:21AM
May-18-23 10:51AM
10:16AM
01:30AM
May-17-23 12:01AM
May-16-23 12:00PM
May-15-23 09:01AM
07:30AM
May-12-23 07:12PM
05:12PM
05:08PM
08:03AM (Thomson Reuters StreetEvents)
May-11-23 07:00AM
May-10-23 01:10PM
11:30AM
11:14AM
May-08-23 07:30AM
May-06-23 09:00AM
08:00AM
07:24AM
May-02-23 09:15AM
12:53AM
May-01-23 02:59PM
Apr-28-23 12:06PM
09:52AM
Apr-27-23 09:45AM
Apr-26-23 04:06PM (Investor's Business Daily)
11:11AM
09:26AM
09:20AM
Apr-25-23 08:00PM
05:45PM
05:22PM (Investor's Business Daily)
04:30PM
11:40AM
Apr-24-23 10:00PM
01:45PM
01:38PM
Apr-21-23 09:00AM
Apr-20-23 08:30AM
Apr-19-23 01:42PM
01:30PM
01:27PM
01:14PM
Apr-18-23 10:00AM
06:04AM
12:00AM
Apr-17-23 10:00PM
12:23PM
09:40AM
Apr-14-23 08:10AM
Apr-12-23 09:15AM
08:01AM
Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; and whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. Further, it provides whole-genome sequencing, genotyping, NIPT, and product support services; and Galleri, a multi-cancer early detection test. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Further, it markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
EPSTEIN ROBERT S Director May 25 Option Exercise 71.09 7,600 540,284 14,764 May 25 04:34 PM Hoyt Aimee L SVP, Chief People Officer Mar 01 Sale 199.06 3,917 779,737 2,881 Mar 03 11:22 AM Aravanis Alexander SVP, Chief Technology Officer Feb 22 Sale 201.74 5,398 1,088,982 2,922 Feb 23 06:08 PM Reeves Kathryne Gambrell SVP, Chief Marketing Officer Feb 21 Option Exercise 0.00 2,789 0 6,973 Feb 23 05:51 PM Pegels Kevin Carl Chief of Global Operations Feb 21 Option Exercise 0.00 1,097 0 7,539 Feb 23 05:46 PM Hoyt Aimee L SVP, Chief People Officer Feb 21 Option Exercise 0.00 5,282 0 8,163 Feb 23 05:42 PM Febbo Phillip G. SVP Chief Medical Officer Feb 21 Option Exercise 0.00 3,522 0 8,475 Feb 23 05:34 PM GOSWAMI JOYDEEP SVP Chief Financial Officer Feb 21 Option Exercise 0.00 4,696 0 12,292 Feb 23 05:38 PM Dadswell Charles SVP & General Counsel Feb 21 Option Exercise 0.00 5,282 0 11,948 Feb 23 05:29 PM Aravanis Alexander SVP, Chief Technology Officer Feb 21 Option Exercise 0.00 9,292 0 12,214 Feb 23 06:08 PM deSouza Francis A President and CEO Feb 21 Option Exercise 0.00 23,473 0 100,419 Feb 23 05:59 PM TOUSI SUSAN H SVP, Chief Commercial Officer Feb 21 Option Exercise 0.00 5,869 0 44,145 Feb 23 05:55 PM TOUSI SUSAN H SVP, Chief Commercial Officer Feb 06 Sale 211.57 500 105,785 38,276 Feb 08 05:29 PM Hoyt Aimee L SVP, Chief People Officer Jan 09 Sale 205.57 871 179,051 2,796 Jan 11 04:27 PM TOUSI SUSAN H SVP, Chief Commercial Officer Jan 06 Sale 204.58 500 102,290 38,662 Jan 10 04:57 PM TOUSI SUSAN H SVP, Chief Commercial Officer Dec 06 Sale 212.63 500 106,315 39,162 Dec 08 04:13 PM Aravanis Alexander SVP, Chief Technology Officer Nov 08 Sale 218.00 361 78,698 2,857 Nov 08 04:56 PM Hoyt Aimee L SVP, Chief People Officer Nov 07 Sale 223.65 1,294 289,403 3,418 Nov 08 05:07 PM TOUSI SUSAN H SVP, Chief Commercial Officer Nov 07 Sale 223.65 500 111,825 40,112 Nov 08 05:14 PM TOUSI SUSAN H SVP, Chief Commercial Officer Oct 06 Sale 216.59 500 108,295 41,333 Oct 11 04:50 PM Aravanis Alexander SVP, Chief Technology Officer Jul 07 Sale 200.00 539 107,800 3,346 Jul 07 05:25 PM TOUSI SUSAN H SVP, Chief Commercial Officer Jun 10 Sale 214.85 250 53,712 41,833 Jun 14 06:20 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite